U.K.-based Myricx Bio has caught the eye of a crop of major investors courtesy of its unique science. It was enough to bring in $114 million via a series A financing that the London-based biotech will use to get two candidates into the clinic over the coming years as well as expand the company’s workforce. Source: Fierce Biotech 8/7/2024